 CAMBRIDGE, Mass., Oct. 01, 2021 GLOBE NEWSWIRE -- Beam Therapeutics Inc. Nasdaq: BEAM, a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present preclinical data from its multiplex edited allogeneic CAR T research targeting CD5-positive hematologic malignancies. The data will be presented in a poster titled CD5 knockout enhances the potency of multiplex base-edited allogeneic anti-CD5 CAR T-cell therapy for the treatment of T-cell malignancies at the Society for Immunotherapy of Cancers SITC 36th Annual Meeting. The conference is being held Nov. 10-14, 2021. 